Novel approaches and targets for treatment of chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 160, Issue 5 II, 1999, Pages

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BRONCHODILATING AGENT; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 8; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; PHOSPHODIESTERASE IV INHIBITOR; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; RETINOID; STEROID; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONFERENCE PAPER; DISEASE ACTIVITY; DRUG EFFICACY; GENE TRANSFER; GENETIC RISK; INFLAMMATION; NEUTROPHIL; PALLIATIVE THERAPY; POWDER INHALER; PRIORITY JOURNAL; TISSUE REPAIR;

EID: 0032724630     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.160.supplement_1.17     Document Type: Conference Paper

References (54)

1. Barnes, P. J. 1998. New therapies for chronic obstructive pulmonary disease. Thorax 53:137-147.
2. Barnes, P. J. 1998. Chronic obstructive pulmonary disease: new opportunities for drug development. Trends Pharmacol. Sci. 19:415-423.
3. a antagonists for clinical use. Life Sci. 60:1053-1060.
4. Barnes, P. J., M. G. Belvisi, J. C. W. Mak, E. Haddad, and B. O'Connor. 1995. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci. 56:853-859.
5. Maesen, F. P. V., J. J. Smeets, T. J. M. Sledsens, F. D. M. Wald, and J. P. G. Cornelissen. 1995. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 8: 1506-1513.
6. Hurt, R. D., D. P. L. Sachs, E. D. Glover, K. P. Offord, J. A. Johnston, L. C. Dale, M. A. Khayrallah, R. Schroeder, P. N. Glover, C. R. Sullivan, L. T. Croghan, and P. M. Sullivan. 1997. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 337:1195-1202.
7. Barnes, P. J., K. F. Chung, and C. P. Page. 1998. Inflammatory mediators of asthma: an update. Pharmacol. Rev. 50:515-596.
8. Zakrzewski, J. T., N. C. Barnes, J. F. Costello, and P. J. Piper. 1987. Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 136:779-782.
9. 4 antagonist LY293I11 on allergen-induced responses in asthma. Thorax 51:1178-1184.
10. Luster, A. D. 1998. Chemokines - chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338:436-445.
11. Keatings, V. M., P. D. Collins, D. M. Scott, and P. J. Barnes. 1996. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 153:530-534.
12. White, J. R., J. M. Lee, P. R. Young, R. P. Hertzberg, A. J. Jurewicz, M. A. Chaikin, K. Widdowson, J. J. Foley, L. D. Martin, D. E. Griswold, and H. M. Sarau. 1998. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem. 273:10095-10098.
13. Kwon, O. J., B. T. Au, P. D. Collins, I. M. Adcock, J. C. Mak, R. A. Robbins, J. M. Baraniuk, K. F. Chung, and P. J. Barnes. 1994. Tumor necrosis factor-induced interleukin 8 expression in cultured human epithelial cells. Am. J. Physiol 11:L398-L405.
14. Repine, J. E., A. Bast, and I. Lankhorst. 1997. Oxidative stress in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 156:341-357.
15. Lundback, B., M. Lindstrom, E. Jonsson, S. Anderson, and C. van Herwaarden. 1995. Effect of N-acetyleysteine on the decline in lung function in patients with COPD. Eur. Respir. J. 5(Suppl. 15):895.
16. Thomas, C. E., D. F. Ohlweiler, A. A. Carr, T. R. Nieduzak, D. A. Hay, G. Adams, R. Vaz, and R. C. Bernotas, 1996. Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps. J. Biol. Chem. 271:3097-3104.
17. 2-III, an index of oxidant stress. Am. J. Respir. Crit. Care Med. 158:1709-1714.
18. 2α, a novel non-cyclooxygenase derived prostaglandin, is a potent constrictor of guinea-pig and human airways. Am. J. Respir. Crit. Care Med. 153:590-596.
19. Llewellyn Jones, C. G., M. M. Johnson, J. L. Mitchell, A. Pye, V. C. Okafor, S. L. Hill, and R. A. Stockley. 1995. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Eur. Respir. J. 8:1479-1487.
20. Jeffery, P. K. 1998. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 53:129-136.
21. McEvoy, C. F., and D. E. Niewoehner. 1997. Adverse effects of corticosteroid therapy for COPD: a critical review. Chest 111:732-743.
22. Keatings, V. M., A. Jatakanon, Y. M. Worsdell, and P. J. Barnes. 1997. Effects of inhaled and oral glucocorticoids on inflammatory induces in asthma and COPD. Am. J. Respir. Crit. Care Med. 155:542-548.
23. Thompson, W. H., C. P. Nielson, P. Carvalho, N. B. Charan, and J. J. Crowley, 1996. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am. J. Respir. Crit. Care Med. 154:407-412.
24. Nielson, C. P., R. E. Vestal, R. J. Sturm, and P. R. Heasli. 1990. Effect of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J. Allergy Clin. Immunol. 86:801-808.
25. Culpitt, S., W. Maziak, S. Loukides, A. Keller, and P. J. Barnes. 1997. Effect of theophylline on induced sputum inflammatory indices in COPD patients (abstract). Am. J. Respir. Crit. Care Med. 157:A797.
26. Barnes, P. J., and M. Karin. 1997. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336:1066-1071.
27. Barnes, P. J., and I. M. Adcock. 1997. NF-κB: a pivotal role in asthma and a new target for therapy. Trends Pharmacol. Sci. 18:46-50.
28. Di Stefano, A., P. Maestrelli, A. Roggeri, G. Turato, S. Calabro, A. Potena, C. E. Mapp, A. Ciaccia, L. Covacev, and L. M. Fabbri. 1994. Up-regulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am. J. Respir. Crit. Care Med. 149: 803-810.
29. Lacraz, S., L. P. Nicod, R. Chicheportiche, H. G. Welgus, and J. M. Dayer. 1995. H.-10 inhibits metalloproteinase and stimulated TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest. 96:2304-2310.
30. Karin, M. 1998. Mitogen-activated protein kinase cascades as regulators of stress responses. Ann. N.Y. Acad. Sci. 851:139-146.
31. Cohen, A. B., W. Girard, J. Mclarty, B. Starcher, M. Stevens, D. S. Fair, D. Davis, H. James, J. Rosenbloom, and U. Kucich. 1990. A controlled trial of colchicine to reduce the elastase load in the lungs of cigarette smokers with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 142:63-72.
32. Williams, J. C., R. C. Falcone, C. Knee, R. L. Stein, A. M. Strimpler, B. Reaves, R. F., Giles, and R. D. Krell. 1991. Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase. Am. Rev. Respir. Dis. 144:875-883.
33. Kawabata, K., M. Suzuki, M. Sugitani, K. Imaki, M. Toda, and T. Miyamoto. 1991. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem. Biophys. Res. Commun. 177:814-820.
34. Luisetti, M., C. Sturani, D. Sella, E. Madonini, V. Galavotti, G. Bruno, V. Peona, U. Kucich, G. Dagnino, J. Rosenbloom, B. Starcher, and C. Grassi. 1996, MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur. Respir. J. 9:1482-1486.
35. Cadene, M., J. Duranton, A. North, M. Si Tahar, M. Chignard, and J. G. Bieth. 1997. Inhibition of neutrophil serine proteinases by suramin. J. Biol. Chem. 272:9950-9955.
36. Finlay, G. A., L. R. O'Driscoll, K. J. Russell, E. M. D'Arcy, J. B. Masterson, M. X. FitzGerald, and C. M. O'Connor, 1997. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am. J. Respir. Crit. Care Med. 156:240-247.
37. Shapiro, S. G., D. K. Kobayashi, and T. J. Ley. 1993. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J. Biol. Chem. 268:23824-23829.
38. Hautamaki, R. D., D. K. Kobayashi, R. M. Senior, and S. D. Shapiro. 1997. Requirement for macrophage metalloelastase for cigarette smoke-induced emphysema in mice. Science 277:2002-2004.
39. Cawston, T. E. 1996. Metalloproteinase inhibitors and the prevention of connective tisue breakdown. Pharmacol. Ther. 70:163-182.
40. Hubbard, R. C., and R. G. Crystal. 1990. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung 168(Suppl.): 565-578.
41. 1 in patients with severe hereditary antitrypsin deficiency. Eur. Respir. J. 10:2260-2263.
42. Sallenave, J. M., J. Shulmann, J. Crossley, M. Jordana, and J. Gauldic. 1994. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and clastase-specific inhibitor (EST/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am. J. Respir. Cell Mol. Biol. 11:733-741.
43. Abbinante-Nissen, J. M., L. G. Simpson, and G. D. Leikauf. 1995. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am. J. Physiol. 12:L601-L606.
44. Llewellyn Jones, C. G., D. A. Lomas, and R. A. Stockley. 1994. Potential role of recombinant secretory leucoprotease inhibitor in the prevention of neutrophil mediated matrix degradation. Thorax 49:567-572.
45. McElvaney, N. G., B. Doujaiji, M. J. Moan, M. R. Burnham, M. C. Wu, and R. G. Crystal. 1993. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am. Rev. Respir. Dis. 148:1056-1060.
46. Vestbo, J., E. Prescott, and P. Lange. 1996. Association of chronic mucus hypersection with FEV1 decline and chronic obstructive pulmonary disease morbidity: Copenhagen City Heart Study Group. Am. J. Respir. Crit. Care Med. 153:1530-1535.
47. Kuo, H., P. J. Barnes, and D. F. Rogers. 1992. Cigarette smoke-induced airway goblet cell secretion: dose dependent differential nerve activation. Am. J. Physiol. 7:L161-L167.
48. Barnes, P. J., M. G. Belvisi, and D. F. Rogers. 1990. Modulation of neurogenic inflammation: novel approaches to inflammalory diseases. Trends Pharmacol. Sci. 11:185-189.
49. Tamaoki, J., A Chiyotani, S. Kobayashi, T. Noritaka, T. Kanemura, and T. Takizawa. 1992. Effect of indomethacin on bronchorrhea with chronic bronchitis, diffuse panbronchiolitis or bronchiectasis. Am. Rev. Respir. Dis. 145:548-552.
50. Kai, H., K. Yoshitake, A. Hisatsune, T. Kido, Y. Isohama, K. Takahama, and T. Miyata. 1996. Dexumethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells. Am. J. Physiol. 271:L484-L488.
51. Goswami, S. K., S. Kivity, and Z. Marom. 1990. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am. Rev. Respir. Dis. 141:72-78.
52. Massaro, G., and D. Massaro. 1997. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nature Med. 3:675-677.
53. Ohmichi, H., U. Koshimizu, K. Matsumoto, and T. Nakamura. 1998. Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development. Development 125: 1315-1324.
54. Barnes, P. J. 1999, Molecular genetics of COPD. Thorax 554:245-252.